TauRx Pharmaceuticals Group Company, WisTa Laboratories Ltd, has been notified by the European Patent Office that they are willing to grant a patent for a group of second-generation rember® derivatives discovered by and under development at the Company. These compounds have the same mechanism of action as rember® acting as Tau Aggregation Inhibitors, with potential utility in the treatment of Alzheimer’s disease and other neurodegenerative disorders. Preclinical and early clinical studies indicate that one of the compounds which delivers the same active moiety as rember® has superior clinical bioavailability and tolerability profiles than rember®, presenting the potential to achieve relatively higher dosing levels and enhanced clinical benefit compared to the already striking clinical effects seen with rember®.